BOSTON, April 10,
2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA),
which is developing the leading platform for cell programming and
biosecurity, today announced the expansion of its strategic
partnership with global healthcare leader Novo Nordisk under a
framework agreement that initially is contemplated to run over five
years.
Novo Nordisk and Ginkgo have created a flexible and scalable new
model for their R&D partnership. Together, the partners aim to
improve the manufacturing of Novo Nordisk's medicines for serious
chronic diseases, including diabetes and obesity medications. The
companies also plan to collaborate on several early pipeline
projects, further technology exploration, and engineering of
scalable manufacturing solutions across Novo Nordisk's
portfolio.
Marcus Schindler, Novo Nordisk
EVP and CSO: "We have been very pleased with the progress
made in our initial work with Ginkgo focused on exploring
strategies for a more effective future production process. We
look forward to leveraging Ginkgo's synthetic biology platform
across our R&D pipeline, from discovery through new
ways of manufacturing, in this broader strategic
partnership. Moreover, we are eager to explore more flexible models
for external partnerships and this agreement allows Novo Nordisk to
start more projects with Ginkgo in a faster and more agile
manner."
Jason Kelly, CEO and
co-founder at Ginkgo Bioworks: "Novo Nordisk has played an
important role in shaping the landscape for pharmaceutical products
in the 21st century. We're so excited to expand our partnership to
help them achieve their ambitious and global goals. With this deal
structure, Novo Nordisk can easily access the entire expanse of
Ginkgo's pharma services from discovery through manufacturing. Our
teams share a deep passion for discovering, developing, and
manufacturing innovative therapeutics for serious chronic diseases
that affect billions of people around the world. We are honored to
work shoulder-to-shoulder with the brilliant scientists, engineers,
and developers at Novo Nordisk to help change disease outcomes for
patients around the world."
To learn more about Ginkgo's offering, visit our webpage or
email us at pharma@ginkgobioworks.com.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell
programming, providing flexible, end-to-end services that solve
challenges for organizations across diverse markets, from food and
agriculture to pharmaceuticals to industrial and specialty
chemicals. Ginkgo's biosecurity and public health unit, Concentric
by Ginkgo, is building global infrastructure for biosecurity to
empower governments, communities, and public health leaders to
prevent, detect and respond to a wide variety of biological
threats. For more information, visit ginkgobioworks.com
and concentricbyginkgo.com, read our blog, or follow us
on social media channels such as X (@Ginkgo and
@ConcentricByGBW), Instagram (@GinkgoBioworks), Threads
(@GinkgoBioworks) or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the capabilities and potential success of the
partnership and Ginkgo's cell programming platform. These
forward-looking statements generally are identified by the words
"believe," "can," "project," "potential," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan,"
"may," "should," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) our ability to realize the
expected benefits of merger and acquisition transactions, (vii) the
outcome of any legal proceedings against Ginkgo, including as a
result of recent acquisitions, (viii) our ability to realize the
expected benefits from and the success of our Foundry platform
programs, (ix) our ability to successfully develop engineered
cells, bioprocesses, data packages or other deliverables, and (x)
the product development or commercialization success of our
customers. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the "Risk Factors" section of
Ginkgo's quarterly report on Form 10-Q filed with the U.S.
Securities and Exchange Commission (the "SEC") on February 29, 2024 and other documents filed by
Ginkgo from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-novo-nordisk-expand-alliance-to-collaborate-across-rd-value-chain-302112781.html
SOURCE Ginkgo Bioworks